Journal article
Dolutegravir
Hospital pharmacy (Philadelphia), Vol.49(2), pp.184-195
02/2014
Handle:
https://hdl.handle.net/2376/101061
PMCID: PMC3940684
PMID: 24623872
Abstract
Each month, subscribers to
The Formulary Monograph Service
receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation/medication use evaluation (DUE/MUE) is also provided each month. With a subscription, the monographs are sent in print and are also available on-line. Monographs can be customized to meet the needs of a facility. A drug class review is now published monthly with
The Formulary Monograph Service.
Through the cooperation of
The Formulary, Hospital Pharmacy
publishes selected reviews in this column. For more information about
The Formulary Monograph Service
, call
The Formulary
at 800-322-4349. The February 2014 monograph topics are sofosbuvir, simeprevir capsules, ibrutinib, hydrocodone extended-release capsules, and eslicarbazepine. The DUE/MUE is on sofosbuvir.
Metrics
12 Record Views
Details
- Title
- Dolutegravir
- Creators
- Dennis J Cada - Founder and Contributing EditorTerri L Levien - Clinical Associate Professor of Pharmacotherapy, Drug Information Center, Washington State UniversityDanial E Baker - Director, Drug Information Center, and Professor of Pharmacy Practice, College of Pharmacy
- Publication Details
- Hospital pharmacy (Philadelphia), Vol.49(2), pp.184-195
- Academic Unit
- Pharmacotherapy, Department of
- Publisher
- Thomas Land Publishers, Inc
- Identifiers
- 99900546656301842
- Language
- English
- Resource Type
- Journal article